Abstract. In many organs the vascular endothelium forms a barrier which impedes the free diffusion of large molecules. The mechanism by which protein hormones are transported through the endothelial cells to reach their target cells is unknown. We have examined the transport of human chorionic gonadotropin (hCG) in rat testicular microvasculature by electron microscopy and by analysing the transfer of radiolabeled hormone and antibodies. Surprisingly, we have observed that the same receptor molecule which is present in target Leydig cells is also involved in transcytosis through the endothelial cells. The hormone was internalized by coated pits and vesicles on the luminal side of the endothelium. It was then localized in the endosomal compartment and subsequently appeared to be delivered by smooth vesicles into the subendothelial space. Moreover, anti-LH/hCG receptor antibodies were efficiently transported via the same system and delivered into the interstitial space. If generalized, these observations may define a new level of modulation of hormone action and may be of importance for drug targeting into the numerous organs which are responsive to the various protein hormones.
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S
YNTHESIS and secretion into the bloodstream of protein hormones have been extensively studied (review in Baulieu and Kelly, 1990) . More recently experimental studies have focused on the interaction of the hormones with their target cells through specific receptors and on the ensuing activation of intracellular signalling pathways (review in Kahn, 1989) . Surprisingly, almost nothing is known on the intermediary steps, i.e., the passage of hormones from the bloodstream into the interstitial space. Most capillary endothelial beds have occluding or fight intercellular junctions that do not permit the free diffusion of molecules of the size of protein hormones (review in Simionescu and Simionescu, 1991) . It is thus necessary to hypothesize for these hormones the existence of as yet non identified transendothelial transport mechanisms. We have examined the passage of human chorionic gonadotropin (hOG) ~ through the continuous endothelium of the testicular microvasculature. We have observed that this transport occurs through a transcytosis mechanism involving the LH/hCG receptor. New regulatory mechanisms may thus exist at this level and may also have important consequences for the practicability of drug targeting.
iodinated by using 1,2,4,6-tetrachloro-3~6c~-diphenylglycouril as described (Fraker and Speck, 1978) . Their specific radioactivity was >30 /~Ci//zg. The radioactive proteins were used at a final concentration of 0.1 /zg/ml PBS, pH 7.3, containing 1 mg/mi of ovalbumin.
Gold Conjugates. LHR729-Au5 m, TSHR51-Au5 m, hCG-Au5 nm, hCGAul0 am, hCG-Au15 ~m, and BSA-Au10 nm complexes were prepared according to standard methods (DeMey, 1986) . For perfusion experiments the gold complexes were resuspended in PBS, pH 7.3, containing 1 mg/ml ovalbumin to a final concentration corresponding to A~m -0.1 for gold particles of 5 nm in diameter, to A~m --0.2 for gold particles of 10 nm in lcm diameter and to A~o nm = 0.3 for gold particles of 15 um in diameter. In some experiments with BSA-Aul0 m the concentration of the tracer was A~0~n~ = 2. The gold conjugates appeared as monodisperse when examined by electron microscopy. As previously described (Saiesse et ai., 1989; Ghinea et al., 1992) both hormone and anti-receptor antibodies coupled to colloidal gold preserve their biological activities. The gold-antibody complexes do not sterically hinder the binding of the gold-hormone conjugates and vice versa (Ghinea et ai., 1992) .
Perfus/on Protoco/s. The a,imals were anesthesized with an intraperitoneal injection of 5% Nesdonai (Specia, Paris) (0.25 mi/100 g body weight). After thoracotomy and exposure of the heart the perfusion was carried out in an open circuit using the left ventricle as the inlet and the opened right atrium as the outlet. The vasculature was washed free of blood by perfusion with '~20 ml of prewarmed (37°C) PBS, pH 7.3, supplemented with 14 mM glucose and gassed with 95 % 02 and 5 % CO2. The perfusate was given under a constant pressure of 75 cm H20 at a flow rate of 5 ml/min for 10 rain. The tracers were then added to the perfusate and maintained in the circulation for various periods of time (5, 10, 15, and 20 rain) . The excess of unbound markers was washed out by perfusion with '~50 mi cold (4°C) PBS, pH 7.3 (in order to stop the transport process), in the same conditions as above. In some experiments the testes were removed, homogenized for counting of radioactivity and for immunoaflinity chromatography. In other experiments the testes were fixed in situ for 15 rain and then overnight with a mixture of 2.5 % glutaraldehyde and 5 % formaldehyde in 0.1 M HCl-sodium cacodylate buffer, pH 7.2. In several experiments fragments of lung, diaphragm, heart, and epidydimal fat were excised and fixed for 90 rain in the same fixative.
Controls. The specificity of the labeling by [125I]hCG and hCG-Aulo m was assayed by perfusing the tracers in the presence of an excess of unlabeled hormone (45/~g of hCG/mi PBS, pH 7.3, containing I mg/mi ovaiburain). The specificity of the immunolabeling of LH/hCG receptors was tested by perfusion with either LHR729-Au5 nm in the presence of 0.1 rag/ ml unlabeled LHR729 or with TSHR51-Au5 ~m (used as a non-related control monoclonai antibody-gold complex).
1Issue Homogenization and Receptor A~inity Chromatography. During its transport towards the Leydig cells, hCG can either bind to the endotheliai or to the Leydig cell receptors or be free (i.e., localized in the interstitial fluid). To follow the fate of the hormone we have perfused in situ the rat vasculature (see above) with [125I]hCG. After 20 rain of perfusion (at 37 ° or 4°C) the intravascular [123I]hCG was washed out with cold (4°C) PBS, pH 7.3, containing 1 mg/ml ovalbumin. The testes were homogenized at 4°C with PBS, pH 7.3, containing a cocktail of protease inhibitors (1 mM benzamidine, 1 mM phenylmethylsulfonylfluoride, 5 mM leupeptin, 1 /zg/mi pepstatin, 40/zg/rnl aprotinin, and 100/zg/mi hacitracin) (buffer A). All further steps were carried out at 4°C. The homogenate was cold (4°C) centrifuged for 60 rain at 105,000 g and the supernatant (SO saved. The pellet was extracted overnight with 1% Triton X-100 in buffer A and centrifuged for 60 min at 105,000 g. The resultant 105,000 g supernatant ($2) was presumed to contain the membrane bound hormone (i.e., [t25I]hCG-LH/hCG receptor complexes). The supernatants Si and $2 were diluted with 2 volumes of buffer A and then applied separately onto an immunomatrix column (0.25 rni of LHR729-Afligal 10) (Vu Hai, 1990 ) at a flow rate of 2 ml/h. The gel was finally washed with 50 volumes of buffer A and counted for radioactivity. IDA 10-Affigel 10 ( Lograin et al., 1983) was used as a non-receptor related immunomatrix control.
Effect of the Hormone on the Transcytosis of LHR729 through the Endothelium. The transendothelial transport of [1~I]LHIU29, fluorescein-LHR729, and LHR729-AU5 m was studied by perfusion in situ in the presence or in the absence of 4.5/~g of hCG/mi of PBS containing I mg/ml ovalbumin. TSHRS1 (Loosfelt et al., 1992) was used as a control non-related monoclonal antibody.
Immunofluorescenee Microscopy, After in situ perfusion with fluorescein-LHR729 (prepared according to Melan and Sluder, 1992 ) the testicular vasculature was fixed by perfusion for 30 rain and then overnight with 3.5% formaldehyde in HCl-sodium-cacodylate, pH 7.2, buffer containing 10% sucrose. Cryostat sections (5-7 pro) were prepared from fixed rat testes and were collected on glass slides. The sections were examined in a Leitz orthoplan microscope using epi-illumination. Color and black and white photographs were taken with Kodak T-Max 400. Fluorescein-TSH51 (prepared according to Melan and Sluder, 1992) Capillaries, arterioles, and venules were identified as previously described (Simionescu and Simionescu, 1984) .
Quantitation. A triplicate experiment was carried out to examine the changes provoked by hormone administration on the distribution and on the transcytosis of LHR729-Au5 m-Ultrathin sections were cut from three randomiy selected blocks of each experiment and 45 capillary profiles (120 endothelial cells) were examined. A total area of 1,500 pm 2 of endothelial cells was examined. Gold particles present on random cell profiles were allocated to one of the following organelles: luminal plasma membrane, coated pits associated with both luminal and ahluminal endothelial fronts, coated vesicles, endosomes (smooth vesicles and tubular structures), multivesicular bodies, abluminal plasma membrane, and subendothelial space (endothelial basal lamina included). The percentage of gold particles associated with each organelle was determined. A total number of 750-800 gold particles were allocated to the different structures, in each experiment.
Results

Transcytosis Pathway of hCG in the Microvascular Endothelium of Rat Testis
To examine the route of the hormone through the vascular endothelium we coupled hCG to gold particles of various diameters, perfused rats at 37°C, and collected testes after various times ofperfusion (5, 10, 15, and 20 rain). We examined by electron microscopy the arteriolar, capillary, and venular endothelial cells. In all these cells and irrespective of particle size, the tracers were internalized and transcytosed by similar routes.
After 5 rain of perfusion, the gold particles were distributed on the plasmalemma proper, the coated pits, and the coated vesicles of the luminal surface of the endothelium (Fig. 1 a) . After 15 rain of perfusion the labeled hormone was also present in the tubulovesicular endosomes (Fig. 1 b) and in large smooth vesicles located near the abluminal side of the endothelium (Fig. 1 c) . At later stages (after 20 rain of perfusion) the hormone-gold complex was located in large smooth vesicles open to the subendothelial space (Fig.  1 e) . A large amount of free gold-labeled hCG was observed in the abluminal space and some tracer was apparently bound to Leydig cell membranes (not illustrated). Some particles were seen in the abluminal coated pits corresponding probably to the re-internalized hormone (Fig. 1 f) . Moreover, a small proportion of the hCG-Au conjugate was present in the multivesicular bodies (Fig. 1, d and f) suggesting an accessory pathway of degradation of the hormone. In these highly pleomorphic structures the gold particles were concentrated on the limiting membrane and their tubular extensions (Fig. 1 d) . In most cases, the internal vesicles of these vacuoles were devoid of labeling (Fig. 1, d and e). No transport of hCG-gold complexes was observed via plasmalemmal vesicles or through the junctions (Fig. 1 a) As a control we used BSA coupled to colloidal gold particles. This tracer has been shown in the rat to cross via plasmalemmal vesicles the continuous endothelium of heart, lung, and adipose tissue (review in Simionescu and Simionescu, 1991) . When the BSA-gold conjugate was perfused through the testes at a concentration similar to that of the hCG-gold complex, only rare particles were seen on the plasmalemma proper and in the plasmalemmal vesicles open to the luminal side of the endothelium (data not shown). At a 20-fold higher concentration of BSA-gold particles some of them were taken up by the plasmalemmal vesicles (never exceeding four particles per vesicle) (Fig. 1 a, inset) suggesting a bulk phase uptake. No BSA was seen passing through the endothelial junctions.
The LH/hCG Receptor Is Involved in Hormone Transcytosis
Observation of hCG-gold complexes in the endothelial cells of testes suggested that they interacted with a membrane protein which tended to accumulate in coated pits and coated vesicles. The similarity of this observation with the initial steps of hormone interaction with Leydig cells (Ghinea et al., 1992) led us to ask the question if the same receptor molecule could be involved in both cases.
We thus used a monoclonal antibody (LHR729) raised against the Leydig cell LH/hCG receptor and conjugated it to colloidal gold. Perfusion experiments were performed as above. After 5 rain of perfusion at 37°C the antibody-gold complex was internalized by the endothelium. Internalization occurred via coated pits (Fig. 2 a) and coated vesicles in a way very similar to that previously observed for hormone-gold conjugate. After 15 min the probe was also observed in tubulo-vesicular endosomes and in large smooth vesicles located near the abluminal cell surface of the endothelium (Fig. 2 b) . A small number of gold particles were seen in the subendothelial space. At longer times of perfusion (20 rain) the proportion of the particles delivered into the subendothelial space via smooth vesicles open to the abluminal front increased as well as after hormone administration (Fig. 2 c, and Table I) .
As in the case of hormone transcytosis, some antibody-gold complex labeled the abluminal coated pits and vesicles (Fig. 2 d) suggesting re-internalization of the antibody and thus, the recycling of the receptor.
Hormone and Receptor Molecules Have Similar Pathways of Transcytosis
To follow ultrastructurally on the same sections the cellular traffic of hormone and receptor we perfused in situ the testicular vasculature with a mixture of labeled hormone (hCGAu~0 m) and of differently labeled anti-receptor antibody The labeled antibody was perfused for 20 rain as described in the absence or presence of hCG. The testes were examined by electron microscopy and the percentage of gold particles associated with each organelle was determined (see Materials and Methods). A total number of 2,400 and 2,250 particles were observed in the experiments in presence and in absence of hCG, respectively.
(LHR729-Aus ~). The results of these double labeling experiments are shown in Fig. 3 . The hormone and the receptor molecules were colocalized on the luminal plasma membrane, in coated pits and vesicles, in tubulo-vesicular endosomes (Fig. 3, a and b) , multivesicular bodies (Fig. 3 c) and smooth vesicles located near the abluminal front of the endothelium. After 20 rain of perfusion both hormone and anti-receptor antibody were delivered into the subendothelial space (Fig. 3 d) . Some particles of both tracers labeled the abluminal plasma membrane and its associated coated pits (Fig. 3 d) .
These results suggested that the hormone was bound by the LH/hCG receptor on the luminal surface of endothelial cells, that the complexes were transcytosed and that the hormone was freed into the subendothelial space. Moreover, an antibody against the receptor could follow the same route and its transport through the endothelial cells could apparently be accelerated by administration of hormone.
Specificity of the Receptor-mediated Endothelial Transcytosis of hCG
To show that the transendothelial transfer of hCG was saturable we perfused the testes with hCG-gold complexes in the presence of a high excess of hCG (45 #g hCG/ml perfusate). This largely suppressed the binding of hCG-gold to the endothelial surface receptor and its subsequent transport (Fig. 4 a) .
Tissue specificity was studied using both hCG and LHR729-gold particles. In organs having a continuous vascular endothelium (heart, lung, diaphragm, and epidydimal fat) both types of complexes failed to label the luminal plas- Fig. 2) . cp, coated pit; cv, coated vesicle; e, endothelium; is, interstitial space;j, endothelial junction; mvb, multivesicular body; pm, plasma membrane; re, tubular endosome; vo, abluminal plasmalemmal vesicle; v,, luminal plasmalemmal vesicle. Bar, 0.1 #m. malemma proper and its associated coated pits. Rarely, a very limited non-specific (fluid-phase) uptake of the tracers was observed occurring through plasmalemmal vesicles (at most one to two particles/vesicle) (Fig. 4, b and c) .
Antibody specificity was studied by perfusing the testes with a gold-tagged monoclonal anti-TSH receptor antibody. In this experiment, some rare gold particles were observed in the plasmalemmal vesicles of endothelial cells (Fig. 4 d) . Species specificity was analyzed by perfusing gold-tagged anti-LH/hCG receptor antibodies in pigs (LHR38 antibody) and in rabbits (LHR285 antibody). In both cases the labeling patterns of the endothelial cells in the testes were similar to those described above in rats (Ghinea, N., M. T. GroyerPicard, and E. Milgrom, manuscript in preparation).
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Transendothelial Transport of~l-labeled hCG and Anti-receptor Antibody
Electron microscopic observations have allowed a detailed description of the cellular pathways which are followed for the hormone and the anti-receptor antibody. However, this method could not yield quantitative data and could not assess the possibility that the hormone delivered to the subendothelial space might be complexed to the extracellular domain of the receptor. To answer these questions we perfused the testes for 20 min with 12SI-labeled hormone. After extensive washing, we measured the free and the membranebound Triton X-100 extractable radioactivity. The latter represented the receptor bound hormone since it was displaced by coperfusion with an excess of unlabeled hormone and since 93 % of it was retained by chromatography through an immunomatrix containing LHR729 antibody (Table 1I ). The Triton-extractable radioactivity obtained after perfusion at low temperature most likely represents the hormone bound to the endothelial receptor. At 37°C transendothelial transport had occurred and there was in addition some binding to the Leydig cell receptors (Table 11 ).
The soluble [lZSI] hCG present in the testes probably represented the hormone which had been transported through the endothelium. This is supported by electron microscopy analysis which shows that unbound hCG-gold complexes are present in the subendothelial space (see Figs. 1 and 3 ). There was very little contamination by residual radioactive hormone remaining inside the blood vessels since soluble p25I]hCG was largely suppressed (Table 17) by coperfusion with unlabeled hormone or by perfusion at low temperature (blood contamination would not have been decreased by excess unlabeled hormone or by low temperature). Thus the soluble [~2q]hCG most likely represented a major fraction of the hormone which has passed the endothelial barrier (although some of this hormone has become attached to Leydig cell membranes) (see above).
Based on this assessment, the transport was negligible at 4°C. It was saturable, as shown by its suppression in the presence of an excess of unlabeled hormone (Table lI) . The solu- [nSI]hCG was perfused for 20 min at 4 ° or 37°C in the absence or in the presence of an excess of unlabeled hormone (see Materials and Methods). Al~er washing by perf~sion of PBS, testicular soluble, and membrane fractions were prepared. The latter was extracted by Triton X-100. Some of the extracts were chromatographed on an immunomatrix containing anti-LH/hCG receptor antibody (see Materials and Methods). The fraction of the hormone retained on the immunomatrix was considered as receptor bound. The (Mostov et al., 1980; Solari et al., 1989) . To examine this hypothesis we perfused testes at 37°C, recovered the soluble fraction and applied it to an immunomatrix containing the LHR729 anti-receptor antibody (this antibody has been shown to recognize the extracellular domain of the receptor (Vu Hai et al., 1990) ). Only 1.6% of the soluble [t25I]hCG did bind to the anti-receptor antibody suggesting that the hormone which has been transported through the endothelial barrier was not complexed to the receptor ectodomain.
Since electron microscopic experiments have suggested a transendothelial transfer of the anti-LH/hCG receptor antibody, we also labeled the latter with [1~I-] and used it for perfusion experiments. For comparison we did similar perfusions with a non-spocific antibody (~25I--labeled anti-TSH receptor antibody, TSHR51) and with [t~I-]albumin. The experiments were performed both in the presence and in the absence of hCG.
As shown in Table 11I some of the anti-LH/hCG receptor antibody was recovered in the Triton X-100 membrane extract. This fraction could correspond to antibodies bound to the receptor. This fraction was increased ~60% by coperfusion of the antibody with hCG. This result may be explained by an increased transendothelial transport in the presence of the hormone (see also Figs. 2 and 3) leading to an increased binding of antibodies to Leydig cell receptors. No significant amounts of the albumin and of the non specific antibody were recovered in this Triton X-100 membrane extract (Table m) . Coperfusion with hCG did not affect this fraction.
As discussed above in the case of pzq-]hCG, we considered the soluble [~I-]LHR729 recovered in the testes as representing a major fraction of the antibodies which had crossed the endothelial barrier. We thus observed that the transport of the anti-LH/hCG receptor antibody was markedly increased (approximately fivefold) by coperfusion with hCG. It was also 20-fold more efficient than that of the control non specific antibody and 12-fold more efficient than that of albumin.
To further examine the transport of the anti-LH/hCG receptor antibody and its subsequent binding to Leydig cell receptors we labeled this antibody with fluorescein, perfused it and examined by light microscopy the distribution of fluorescence in the testes (Fig. 5) . AS expected, the endothelial cells were strongly labeled (Fig. 5 a) and the antibody had reached the surface of the Leydig cells (Fig. 5 b) . When a control fluorescein-labeled monoclonal antibody (Fluorescein-TSH51) was used only a weak signal was de- tected spread diffusely through the interstitial space (not shown).
Discussion
The microvascular endothelium forms a thin and continuous layer of squamous epithelial cells which separates the blood from the interstitial fluid. Endothelial cells are polarized and linked one to another by junctional complexes (tight and gap junctions) which ensure the continuity and mark the transition between the luminal (blood) and abluminal fronts. Ultrastructural and cytochemical studies (review in Simionescu and Simionescu, 1991) have shown that the microvascular endothelium constitutes a major barrier for the bidirectional exchanges of macromolecules between the plasma and the interstitial fluid. In vivo experiments involving injection of labeled proteins have confirmed this morphological finding showing that several hours are required for vascular/ interstitial equilibration of radioactive plasma proteins (Larson et al., 1984; Powers and Bell, 1990; Ghitescu and Bendayan, 1992) .
All these studies involved proteins present in relatively high concentration in blood. The route of the transendothelial transport of these proteins has also been studied. It was shown that they reach the interstitial space via plasmalemmal vesicles and transendothelial channels (Simionescu et al., 1975) . This process involves a non-specific fluid phase mechanism (Williams, 1983 ) the efficiency of which is limited and depends on the number of plasmalemmal vesicles, on the plasma concentration of the proteins and on their size, shape, and charge (Simionescu et al., 1972; Ghinea and Simionescu, 1985; Ghinea and Hasu, 1986; Ghinea, 1987; Simionescu and Ghinea, 1990) . It has also been observed that plasma proteins (for instance albumin) may interact in the plasmalemmal vesicles with low-affinitybinding proteins (Ghitescu et al., 1986; Milici et al., 1987; Ghinea et al., 1988; Schnitzer et al., 1988; Ghinea et al., 1989) . It seems unlikely that protein hormones, which are present in blood at very low concentrations and which fluctuate rapidly in order to give sharp biological effects, could follow this route. Surprisingly very little information is available on the transendothelial transport of protein and glycoprotein hormones.
In the present study we have used both biochemical and morphological approaches to determine the transendothelial route of hCG towards its target Leydig cells in rat testis. We have observed its interaction with an endothelial cell membrane component which we have identified by immunocytochemistry and immunopurification (see Table II ) as the LH/hCG receptor. Its interaction, in different species, with several monoclonal anti-receptor antibodies (LHR729, 38, and 285) recognizing different epitopes (V. Hal, unpublished results), confirmed this identification. Furthermore, a recent study confirmed the presence of LH/hCG receptor in rat ovarian and testicular blood vessels (Bukovsky et al., 1993) .
The transcytosis of hCG occurs in several steps: the hormone molecules first bind to specific receptors expressed on the luminal front, then they are concentrated in coated pits and transferred via coated vesicles to an extensive smooth tubulo-vesicular endosome system (at present, the exact steps in the transition from coated vesicles to endosomes are not well characterized). The hormone and the receptor are then directed to the abluminal front by means of smooth transcytotic vesicles that pinch off from the tubular extensions of the endosomes. These vesicles became inserted into the abluminal endothelial plasma membrane and, finally, the hormone is released into the subendothelial space.
Our results also indicate that a small proportion of the hCG-gold conjugate leaves the endosomes and enters the multivesicular bodies. This fraction of hormone may thus be engaged in a pathway leading to its degradation. However, there is a possibility that some of the tracer is carded towards the abluminal cell surface by smooth transcytotic vesicles, derived from the tubular extensions of the multivesicular bodies. Such a mechanism has been reported for the transfertin receptor in other cell types (Harding et al., 1983; Hopkins, 1983) .
The dissociation mechanism of the hormone-receptor complex on the abluminal cell surface is unknown. Covalent posttranslational modifications of the receptor, e.g., phosphorylation (Hipkin et al., 1993) and possible differences between the intraluminal pH of the transcytotic vesicles (derived from endosomes) and the physiological pH of the interstitial fluid may induce reversible conformational changes in the LH/hCG receptor molecule. These structural modifications would allow continuous hormone delivery and shutfling of the receptor across the endothelial cells. The reinternalization of the receptor on the endothelial abluminal cell surface seems to occur via coated pits and vesicles.
The route followed by hormone-receptor complexes in endothelial cells differs from the endocytosis previously described in Leydig cells and in transfected L cells (Ghinea et al., 1992) . In the latter the complexes are directed towards the lysosomes. The tubulo-vesicular endosomes seem to be the place where different sorting mechanisms orient the hormone-receptor complexes along different pathways. This suggests the existence in Leydig and in endothelial cells of different signals on the cytoplasmic domain of the receptor (for instance different phosphorylation patterns) or of interactions with different "sorting" proteins (Goud and McCaffrey, 1991; Bomsel and Mostov, 1992) .
Transcytosis, involving tubulo-vesicular endosomes has never, to our knowledge, been described in endothelial cells. However, such a mechanism has been observed in various epithelial cells for the transcytosis of thyroglobulin (Herzog, 1983) , epidermal growth factor (Maratos-Flier et al., 1987) , nerve growth factor (Siminoski et al., 1986) , transferrin (Seddiki et al., 1992) , IgG (Rodewald and Kraehenbuhl, 1984; Parham, 1989) , IgM, and IgA (Geuze et al., 1984; Hoppe et al., 1985; Mostov and Simister, 1985) . In the latter case some of the sorting mechanisms discussed above have been elucidated: Casanova et al. (1990) have shown that if the serine 664 of the polymer IgA receptor is replaced by an alanine the receptor keeps its property of internalization but fails to be sorted efficiently out of the endocytic route. Phosphorylation of serine 664 is thus probably important for the correct orientation of the receptor towards its transcytotic route.
Although we have used polyvalent tracers (hCG-gold and LHR729-gold complexes) to observe the fate of hormone and antibody, the morphological conclusions were consistent with other experiments involving iodinated or fluoresceinlabeled monomeric equivalents.
How general is the mechanism of receptor-mediated hor-mone transcytosis in endothelial cells is difficult to determine at present. We have gathered some preliminary evidence that hCG is transported through a similar mechanism in the ovarian microvasculature (N. , 1992) . Taken together these observations suggest that the mechanism described in the present study may be of more general significance. Further studies will be necessary to establish if this transport mechanism may be regulated: for instance if there is a hormone induced down-regulation of the endothelial receptor which could decrease hormone transport and contribute to the desensitization of hormone action. It will be also important to establish whether the receptor-mediated transcytosis is restricted to the endothelium of target organs or whether it also exists in hormone producing organs. In the latter case the transport of hormones would occur in the opposite direction (from the abluminal endothelial front to the vascular lumen). Hormone transport may also display different characteristics in fenestrated endothelia though protein transport does not seem to occur through the fenestrae (Simionescu et al., 1981).
Our results have also shown that the anti-receptor antibodies can be actively transported through the testicular endothelial barrier by the LH/hCG receptor-mediated transcytosis system. Drug targeting using monoclonal antibodies is extensively studied (reviewed in Goldberg, 1993; Rubin, 1993) . Very often such antibodies linked to drugs or to toxins prove very effective in vitro on model cell culture systems but fail to be active in vivo in whole animals or in patients. Various hypotheses have been discussed in such cases (reviewed in Jain, 1989) We wish to thank Dr. D. Louvard (Institut Pasteur, Paris, France) for his helpful discussions and Dr. G. E. Palade (University of California, San Diego, CA) for his comments on the manuscript. We are grateful to Martine Guerrois, Val6rie Coquondeau, and Anh-Dao Daklhia for word processing.
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